Author: Rebecca Shover
Medical Experts
“Follow every word of advice from every medical expert on TV, radio, books, magazines and...
Read More
Quadruple Therapy Phase II Data for EGFR-mutated NSCLC
Atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) is a promising regimen for...
Read More
Determining Whether Adding RP1 to Cemiplimab Helps CSCC Patients
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read More
Acalabrutinib Still Outperforming in R/R CLL: Three-years Follow-up of ASCEND
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read More
Dr. MedLaw: Restrictive Covenant
Q: All the employed doctors at my hospital, even those who were not up for contract renewal, just...
Read More
OS benefit seen in 5-year data on ELEVATE-TN trial in CLL
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read More
Add-on Tiragolumab Doesn’t Improve on Atezolizumab in Extensive Stage Small Cell Lung Cancer
A Late-breaking session at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting,...
Read More
Randomized Trial for High-risk Cutaneous Squamous Cell Carcinoma Patients Treated With Adjuvant Cemiplimab
High-risk patients with cutaneous squamous cell carcinoma (CSCC) have an unmet need with regard to...
Read More
Panitumumab Beats Bevacizumab in RAS Wild-type Left-sided Metastatic Colorectal Cancer
Panitumumab was superior to bevacizumab when added to mFOLFOX6 as first-line therapy in patients...
Read More
Dr. MedLaw: EMTALA Violation
Q: I am on an ad hoc committee at my hospital looking into an EMTALA problem that we are trying to...
Read More
Pill Colors
“Right now I take a blue pill, a purple pill, an orange pill, a white pill, and a yellow...
Read More
Financial Toxicity Has ‘Profound Impact’ in Gynecologic Oncology
Patients undergoing surgery for gynecologic cancer, particularly those without insurance,...
Read More
SKYSCRAPER-02: Additional Tiragolumab Does Not Help Patients With Untreated SCLC
Tiragolumab, added to atezolizumab, carboplatin, and etoposide, did not improve the...
Read More